GSDME and neoplasm: Recent studies have highlighted that diverse small-molecule inhibitors can enhance therapeutic efficacy, tackle drug resistance and improve anti-tumor immunotherapy by activating the caspase-3/GSDME pathway-mediated pyroptosis [17–20].